<DOC>
	<DOCNO>NCT00044681</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety risperidone augment SSRI therapy patient treatment-resistant depression demonstrate long-term maintenance effect risperidone augmentation therapy compare placebo augmentation patient .</brief_summary>
	<brief_title>A Study Effectiveness Safety Risperidone Augment SSRI Therapy Patients With Treatment-resistant Depression</brief_title>
	<detailed_description>Treatment strategy treatment-resistant depression ( TRD ) involve either switch another antidepressant , augment first-line treatment various pharmacologic agent , switch different medication combination another agent . This study include 2 phase : open-label treatment phase double-blind maintenance phase , neither patient physician know whether risperidone placebo administer . The open-label phase initial period 6 week patient TRD receive citalopram , selective serotonin reuptake inhibitor ( SSRI ) . Risperidone add treatment regimen 4 week evaluate short-term effect augment therapy . The double-blind phase last 6 month evaluate relapse prevention continue risperidone augmentation therapy compare placebo augmentation SSRI . Targeted daily dos citalopram risperidone adjust young adult ( 18 54 year age ) old adult ( 55 85 year age ) . Assessments effectiveness include Montgomery-Asberg Depression Rating Scale ( MADRS ) ; Hamilton Rating Scale Depression ( HAM-D ) ; Clinical Global Impression Severity ( CGI-S ) ; response rate , determine proportion patient show &gt; =50 % improvement MADRS total score ; relapse , evaluate change CGI HAM-D score . Safety evaluation include incidence adverse event throughout study , vital sign ( pulse blood pressure ) weight , clinical laboratory test ( hematology , biochemistry , urinalysis ) specify interval . The study hypothesis risperidone augmentation SSRI therapy show significant improvement symptom depression compare SSRI monotherapy risperidone augmentation show good time-to-relapse placebo augmentation patient TRD . Once daily , oral tablet risperidone ( 0.25 milligram [ mg ] , 0.5mg , 1.0mg , 2.0mg ) , citalopram ( 20mg 40mg ) placebo . Risperidone 30 week ; 0.25-2.0mg younger adult , 0.25-1.0mg older adult . Citalopram 36 week ; 20-60 mg young adult ; 20-40 mg old adult .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Meet criterion Diagnostic Statistical Manual Mental Diseases , 4th edition ( DSMIV ) , Major Depressive Disorder history resistance therapy antidepressant medication score Hamilton Rating Scale Depression ( HAMD ) &gt; =20 start study . Meet DSMIV criterion Axis I disorder ( except anxiety disorder ) borderline personality disorder substance dependence , include drug abuse alcohol history schizophrenia , bipolar disorder , manic episode meet DSMIV criterion delirium , dementia , amnesic cognitive disorder support Mini Mental Status Examination ( MMSE ) pregnant nursing female , lack adequate contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Risperidone</keyword>
	<keyword>depression</keyword>
	<keyword>melancholia</keyword>
	<keyword>depressive disorder</keyword>
	<keyword>antipsychotic agent</keyword>
</DOC>